During the last session, CytomX Therapeutics Inc (NASDAQ:CTMX)’s traded shares were 4.12 million, with the beta value of the company hitting 2.12. At the end of the trading day, the stock’s price was $2.11, reflecting an intraday loss of -11.34% or -$0.27. The 52-week high for the CTMX share is $3.10, that puts it down -46.92 from that peak though still a striking 81.04% gain since the share price plummeted to a 52-week low of $0.40. The company’s market capitalization is $332.42M, and the average intraday trading volume over the past 10 days was 2.73 million shares, and the average trade volume was 4.70 million shares over the past three months.
CytomX Therapeutics Inc (CTMX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. CTMX has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
CytomX Therapeutics Inc (NASDAQ:CTMX) trade information
CytomX Therapeutics Inc (CTMX) registered a -11.34% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -11.34% in intraday trading to $2.11, hitting a weekly high. The stock’s 5-day price performance is -25.18%, and it has moved by -0.94% in 30 days. Based on these gigs, the overall price performance for the year is 52.90%. The short interest in CytomX Therapeutics Inc (NASDAQ:CTMX) is 18.96 million shares and it means that shorts have 1.78 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.84, which implies an increase of 63.87% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.25 and $8 respectively. As a result, CTMX is trading at a discount of -279.15% off the target high and -54.03% off the low.
While earnings are projected to return -124.50% in 2025.
CTMX Dividends
CytomX Therapeutics Inc is due to release its next quarterly earnings on 2025-May-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
CytomX Therapeutics Inc (NASDAQ:CTMX)’s Major holders
CytomX Therapeutics Inc insiders own 0.83% of total outstanding shares while institutional holders control 51.04%, with the float percentage being 51.47%. TANG CAPITAL MANAGEMENT LLC is the largest shareholder of the company, while 82.0 institutions own stock in it. As of 2024-06-30, the company held over 7.79 million shares (or 9.1799% of all shares), a total value of $9.51 million in shares.
The next largest institutional holding, with 6.3 million shares, is of JANUS HENDERSON GROUP PLC’s that is approximately 7.4245% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $7.72 million.
